This study aimed to analyze the expression of the high mobility group box-1 (HMGB1) protein in neutrophil extracellular traps (NETs) of patients with lupus nephritis (LN) and its association with clinical and histopathological features of the disease.
Methods
Twenty-three patients with biopsy-confirmed LN and 14 systemic lupus erythematosus (SLE) patients with active disease (SLE Disease Activity Index (SLEDAI) score ≥ 6) and no evidence of LN were included. Clinical and laboratory features were recorded. NETs and the expression of HMGB1 were assessed by confocal microscopy, and serum HMGB1 levels were measured by ELISA.
Results
In comparison to patients without kidney disease, patients with LN had a higher expression of HMGB1 in spontaneous (57 vs. 30.4; p = 0.027) and lipopolysaccharide (LPS)-induced (55.8 vs. 24.9; p = 0.005) NETs. We found a positive correlation between serum HMGB1 and the expression of HMGB1 in LPS-induced NETs (r = 0.447, p = 0.017). The expression of HMGB1 in spontaneous NETs correlated with SLEDAI score (r = 0.514, p = 0.001), anti-dsDNA antibodies (r = 0.467, p = 0.004), the rate of glomerular filtration descent (r = 0.543, p = 0.001), and diverse histopathological components of active nephritis in the kidney biopsy, such as the activity index (r = 0.581, p = 0.004), fibrinoid necrosis (r = 0.603, p = 0.002), and cellular crescents (r = 0.486, p = 0.019).
Conclusions
In patients with SLE, NETs are a source of extracellular HMGB1. The expression of HMGB1 in NETs is higher among patients with LN, which correlates with clinical and histopathological features of active nephritis and suggest a possible role of this alarmin in the pathophysiology of kidney damage in SLE.
BertsiasGKSalmonJEBoumpasDT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis2010; 69: 1603–1611.
2.
AlarconGS. Multiethnic lupus cohorts: what have they taught us?Reumatol Clin2011; 7: 3–6.
3.
VillanuevaEYalavarthiSBerthierCC, et al.Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol2011; 187: 538–552.
4.
Garcia-RomoGSCaielliSVegaB, et al.Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med2011; 3: 73ra20–73ra20.
5.
KaplanMJ. Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol2011; 7: 691–699.
6.
ApelFZychlinskyAKennyEF. The role of neutrophil extracellular traps in rheumatic diseases. Nat Rev Rheumatol2018; 14: 467–475.
7.
BanchereauRHongSCantarelB, et al.Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell2016; 165: 1548–1550.
BrinkmannVReichardUGoosmannC, et al.Neutrophil extracellular traps kill bacteria. Science2004; 303: 1532–1535.
10.
HarrisHEAnderssonUPisetskyDS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol2012; 8: 195–202.
11.
PanHFWuGCLiWP, et al.High mobility group box 1: a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep2010; 37: 1191–1195.
12.
VenereauECasalgrandiMSchiraldiM, et al.Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med2012; 209: 1519–1528.
13.
JankoCFilipovicMMunozLE, et al.Redox modulation of HMGB1-related signaling. Antioxid Redox Signal2014; 20: 1075–1085.
14.
YangHAntoineDJAnderssonU, et al.The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol2013; 93: 865–873.
15.
QingXPitashnyMThomasDB, et al.Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury. Immunol Lett2008; 121: 61–73.
16.
LiJXieHWenT, et al.Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol2010; 37: 766–775.
17.
LiXYueYZhuY, et al.Extracellular, but not intracellular HMGB1, facilitates self-DNA induced macrophage activation via promoting DNA accumulation in endosomes and contributes to the pathogenesis of lupus nephritis. Mol Immunol2015; 65: 177–188.
18.
FengXJWuCYanGF, et al.TLR2 plays a critical role in HMGB1-induced glomeruli cell proliferation through the FoxO1 signaling pathway in lupus nephritis. J Interferon Cytokine Res2016; 36: 258–266.
19.
ZickertAPalmbladKSundelinB, et al.Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther2012; 14: R36–R36.
20.
AbdulahadDAWestraJBijzetJ, et al.Urine levels of HMGB1 in systemic lupus erythematosus patients with and without renal manifestations. Arthritis Res Ther2012; 14: R184–R184.
21.
JogNRBlancoILeeI, et al.Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. Lupus2016; 25: 1551–1557.
22.
WirestamLSchierbeckHSkoghT, et al.Antibodies against high mobility group box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus. Arthritis Res Ther2015; 17: 338–338.
23.
PilzwegerCHoldenriederS. Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases. Diagnostics2015; 5: 219–253.
24.
MaCYJiaoYLZhangJ, et al.Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int2012; 32: 395–402.
25.
BruschiMPetrettoASantucciL, et al.Neutrophil extracellular traps protein composition is specific for patients with lupus nephritis and includes methyl-oxidized alphaenolase (methionine sulfoxide 93). Sci Rep2019; 9: 7934–7934.
26.
CoppoPCJBengoufaDOksenhendlerELacroixCLassouedK. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology (Oxford)2002; 41: 1040–1046.
27.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
28.
PetriMOrbaiAMAlarconGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
29.
Romero-DiazJIsenbergDRamsey-GoldmanR. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res2011; 63: S37–46.
30.
CliftonLBirksJCliftonDA. Comparing different ways of calculating sample size for two independent means: a worked example. Contemp Clin Trials Commun2019; 13: 100309–100309.
31.
YuFHaasMGlassockR, et al.Redefining lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol2017; 13: 483–495.
32.
Carmona-RiveraCKaplanMJ. Induction and quantification of NETosis. Curr Protoc Immunol2016; 115: 14.41.1–14.41.14.
33.
Carmona-RiveraCZhaoWYalavarthiS, et al.Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis2015; 74: 1417–1424.
34.
GuptaSKaplanMJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol2016; 12: 402–413.
35.
ChengFJZhouXJZhaoYF, et al.Human neutrophil peptide 1-3, a component of the neutrophil extracellular trap, as a potential biomarker of lupus nephritis. Int J Rheum Dis2015; 18: 533–540.
36.
ZhangSLuXShuX, et al.Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus. Intern Med2014; 53: 2763–2771.
37.
WenZXuLChenX, et al.Autoantibody induction by DNA-containing immune complexes requires HMGB1 with the TLR2/microRNA-155 pathway. J Immunol2013; 190: 5411–5422.
38.
SchaperFde LeeuwKHorstG, et al.Autoantibodies to box A of high mobility group box 1 in systemic lupus erythematosus. Clin Exp Immunol2017; 188: 412–419.
39.
AbdulahadDAWestraJBijzetJ, et al.High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther2011; 13: R71–R71.
40.
TianJAvalosAMMaoSY, et al.Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol2007; 8: 487–496.
41.
EunSYKoYSParkSW, et al.IL-1beta enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release. Vascul Pharmacol2015; 72: 108–117.
42.
FengXHaoJLiuQ, et al.HMGB1 mediates IFN-gamma-induced cell proliferation in MMC cells through regulation of cyclin D1/CDK4/p16 pathway. J Cell Biochem2012; 113: 2009–2019.
43.
FairhurstAMXieCFuY, et al.Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol2009; 183: 6831–6838.
44.
van Dam LS, Kraaij T, Kamerling SWA, et al. Neutrophil extracellular trap formation is intrinsically distinct in ANCA-associated vasculitis and systemic lupus erythematosus. Arthritis Rheumatol. Epub ahead of print 16 July 2019 2019. DOI: 10.1002/art.41047.
